AbbVie (NYSE:ABBV) Shares Down 1% – What’s Next?

AbbVie Inc. (NYSE:ABBV)’s share price traded down 1% during trading on Thursday . The company traded as low as $223.57 and last traded at $225.3580. 7,596,307 shares were traded during trading, an increase of 5% from the average session volume of 7,209,400 shares. The stock had previously closed at $227.68.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie advanced a risankizumab dosing study (Phase 1), signaling continued investment in immunology which supports longer-term revenue diversification beyond Humira. AbbVie Advances Risankizumab Dosing Study
• Positive Sentiment: AbbVie reported encouraging Phase 1 results for ABBV‑295, adding early-stage pipeline value that could translate into mid/long-term upside if later trials confirm activity and safety. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: RBC Capital initiated coverage with an Outperform and $260 target, reflecting conviction in Skyrizi/Rinvoq growth and providing analyst support for the shares. RBC Capital Says AbbVie Growth Story Is Still in Early Stages
• Neutral Sentiment: Market commentary shows split analyst views — fair-value estimates moved only slightly, leaving a balanced risk/reward view that tempers immediate upside expectations. How The Narrative For AbbVie Is Shifting
• Neutral Sentiment: Broader market reports forecast growth in bipolar-depression and psychiatric markets — a potential long-term tailwind for psychiatric assets but not an immediate catalyst. Bipolar Depression Market Expected to Witness Accelerated Expansion
• Negative Sentiment: Skyrizi was outperformed by UCB’s Bimzelx in psoriatic arthritis data — a competitive loss that could pressure market share and growth assumptions for Skyrizi. Skyrizi beaten by UCB’s Bimzelx
• Negative Sentiment: Reported insider selling has appeared in market headlines, a near-term bearish signal that can amplify selling pressure even if fundamentals remain intact. AbbVie Stock Price Down on Insider Selling

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ABBV. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Finally, Barclays started coverage on AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Stock Down 1.0%

The firm has a market capitalization of $398.47 billion, a PE ratio of 95.49, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34. The firm has a 50-day moving average price of $224.58 and a 200 day moving average price of $224.47.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s dividend payout ratio is currently 293.22%.

Insider Buying and Selling at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.25% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ABBV. Norges Bank purchased a new stake in shares of AbbVie in the fourth quarter valued at approximately $5,865,055,000. Wellington Management Group LLP boosted its stake in shares of AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Capital World Investors raised its holdings in AbbVie by 106.3% during the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after purchasing an additional 6,736,161 shares during the last quarter. Laurel Wealth Advisors LLC grew its holdings in AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the last quarter. Finally, Cardano Risk Management B.V. increased its position in shares of AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after buying an additional 4,908,260 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.